+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country

  • ID: 5232505
  • Report
  • December 2020
  • Region: Asia Pacific
  • 136 pages
  • GMD Research
1 of 4

FEATURED COMPANIES

  • Aenova Group
  • CMIC Co. Ltd
  • Hospira, Inc.
  • Lonza Group
  • Pfizer CentreSource
  • Recipharm AB
  • MORE
Asia-Pacific's pharmaceutical CDMO market will grow by 8.3% annually with a total addressable market cap of $725.2 billion over 2020-2030 owing to the rising demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures.

Highlighted with 44 tables and 53 figures, this 136-page report “Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” is based on comprehensive research of the entire Asia-Pacific pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies of the period 2015-2019 and provides a forecast from 2020 till 2030 with 2019 as the base year.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces
The trend and outlook of Asia-Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia-Pacific pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country.

Based on Category, the Asia-Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Pharmaceutical Industry
  • Biopharmaceutical Industry
Based on Service Type, the Asia-Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Pharmaceutical Contract Manufacturing Organization (CMO)
  • Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
  • Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
  • Secondary Packaging
Pharmaceutical Contract Research Organization (CRO)
  • CRO for Pre-clinical Development
  • CRO for Phase I Trials
  • CRO for Phase II Trials
  • CRO for Phase III Trials
  • CRO for Phase IV Trials
  • Laboratory Services
  • Consulting Services
  • Data Management Services
Based on Therapeutic Application, the Asia-Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Infectious Diseases
  • Oncology
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Central Nervous System
  • Pulmonary Disorders
  • Gastrointestinal Disorders
  • Other Therapeutic Applications
Based on End User, the Asia-Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Academic Institutes
Geographically, the following national/local markets are fully investigated:
  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia-Pacific pharmaceutical CDMO market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Company Profiles of CMO:
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
Company Profiles of CRO:
  • Charles River Laboratories
  • CMIC Co. Ltd
  • Covance Inc.
  • Hangzhou Tigermed Consulting Co Ltd
  • ICON Plc
  • IQVIA Holdings Inc.
  • LSK Asia-Pacific Pharma Service Co Ltd
  • Novotech Pty Ltd
  • PAREXEL International Corporation
  • Pharmaceutical Product Development LLC (PPD)
  • PRA Health Sciences Inc.
  • Quanticate Ltd
  • Samsung Bioepis Co. Ltd
  • SGS SA (SGS Life Sciences)
  • Syneos Health Inc.
  • WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aenova Group
  • CMIC Co. Ltd
  • Hospira, Inc.
  • Lonza Group
  • Pfizer CentreSource
  • Recipharm AB
  • MORE
1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 Segmentation of Asia-Pacific Market by Category
3.1 Market Overview by Category
3.2 Pharmaceutical Industry
3.3 Biopharmaceutical Industry

4 Segmentation of Asia-Pacific Market by Service Type
4.1 Market Overview by Service Type
4.2 Pharmaceutical Contract Manufacturing Organization (CMO)
4.2.1 Active Pharmaceutical Ingredients (API)
4.2.2 Finished Dosage Formulations (FDF)
4.2.3 Secondary Packaging
4.3 Pharmaceutical Contract Research Organization (CRO)
4.3.1 CRO for Pre-clinical Development
4.3.2 CRO for Phase I Trials
4.3.3 CRO for Phase II Trials
4.3.4 CRO for Phase III Trials
4.3.5 CRO for Phase IV Trials
4.3.6 Laboratory Services
4.3.7 Consulting Services
4.3.8 Data Management Services

5 Segmentation of Asia-Pacific Market by Therapeutic Application
5.1 Market Overview by Therapeutic Application
5.2 Infectious Diseases
5.3 Oncology
5.4 Metabolic Disorders
5.5 Cardiovascular Disorders
5.6 Central Nervous System
5.7 Pulmonary Disorders
5.8 Gastrointestinal Disorders
5.9 Other Therapeutic Applications

6 Segmentation of Asia-Pacific Market by End User
6.1 Market Overview by End User
6.2 Pharmaceutical & Biopharmaceutical Companies
6.3 Medical Device Companies
6.4 Academic Institutes

7 Asia-Pacific Market 2019-2030 by Country
7.1 Overview of Asia-Pacific Market
7.2 Japan
7.3 China
7.4 Australia
7.5 India
7.6 South Korea
7.7 Rest of APAC Region

8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
8.3.1 Company Profiles of CMO
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO
  • Charles River Laboratories
  • CMIC Co. Ltd
  • Covance Inc.
  • Hangzhou Tigermed Consulting Co Ltd
  • ICON Plc
  • IQVIA Holdings Inc.
  • LSK Asia-Pacific Pharma Service Co Ltd
  • Novotech Pty Ltd
  • PAREXEL International Corporation
  • Pharmaceutical Product Development LLC (PPD)
  • PRA Health Sciences Inc.
  • Quanticate Ltd
  • Samsung Bioepis Co. Ltd
  • SGS SA (SGS Life Sciences)
  • Syneos Health Inc.
  • WuXi AppTec Inc.
9 Investing in Asia-Pacific Market: Risk Assessment and Management
9.1 Risk Evaluation of Asia-Pacific Market
9.2 Critical Success Factors (CSFs)

List of Tables
Table 1. Snapshot of Asia-Pacific Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn
Table 4. Worldwide Total Number of Registered Clinical Trials
Table 5. Main Product Trends and Market Opportunities in Asia-Pacific Pharmaceutical CDMO Market
Table 6. Asia-Pacific Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 7. Asia-Pacific Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 8. Asia-Pacific Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn
Table 9. Asia-Pacific Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn
Table 10. Asia-Pacific Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn
Table 11. Asia-Pacific Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn
Table 12. Asia-Pacific Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 13. Asia-Pacific Pharmaceutical CDMO Market by End User, 2019-2030, $ bn
Table 14. APAC Pharmaceutical CDMO Market by Country, 2019-2030, $ bn
Table 15. Japan Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 16. Japan Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 17. Japan Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 18. China Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 19. China Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 20. China Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 21. Australia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 22. Australia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 23. Australia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 24. India Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 25. India Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 26. India Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 27. South Korea Pharmaceutical CDMO Market by Category, 2019-2030, $ bn
Table 28. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn
Table 29. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn
Table 30. Pharmaceutical CDMO Market in Rest of APAC by Country, 2019-2030, $ bn
Table 31. Breakdown of World CMO Market by Key Vendor, 2019, %
Table 32. Breakdown of World CRO Market by Key Vendor, 2019, %
Table 33. Aenova Group: Company Snapshot
Table 34. Aenova Group: Business Segmentation
Table 35. Aenova Group: Product Portfolio
Table 36. Aenova Group: Revenue, 2016-2018, $ bn
Table 37. Aenova Group: Recent Developments
Table 38. Charles River Laboratories: Company Snapshot
Table 39. Charles River Laboratories: Business Segmentation
Table 40. Charles River Laboratories: Product Portfolio
Table 41. Charles River Laboratories: Revenue, 2016-2018, $ bn
Table 42. Charles River Laboratories: Recent Developments
Table 43. Risk Evaluation for Investing in Asia-Pacific Market, 2019-2030
Table 44. Critical Success Factors and Key Takeaways

List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia-Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Asia-Pacific Pharmaceutical CDMO Market, 2019-2030, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia-Pacific Pharmaceutical CDMO Market
Figure 8. Primary Restraints and Impact Factors of Asia-Pacific Pharmaceutical CDMO Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Fiver Forces Analysis of Asia-Pacific Pharmaceutical CDMO Market
Figure 11. Breakdown of Asia-Pacific Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue
Figure 12. Asia-Pacific Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)
Figure 13. Asia-Pacific Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn
Figure 14. Asia-Pacific Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn
Figure 15. Breakdown of Asia-Pacific Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue
Figure 16. Asia-Pacific Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%)
Figure 17. Asia-Pacific Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn
Figure 18. Asia-Pacific Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn
Figure 19. Asia-Pacific Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn
Figure 20. Asia-Pacific Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn
Figure 21. Asia-Pacific Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn
Figure 22. Asia-Pacific Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn
Figure 23. Asia-Pacific Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn
Figure 24. Asia-Pacific Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn
Figure 25. Asia-Pacific Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn
Figure 26. Asia-Pacific Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn
Figure 27. Asia-Pacific Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn
Figure 28. Asia-Pacific Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn
Figure 29. Asia-Pacific Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn
Figure 30. Breakdown of Asia-Pacific Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue
Figure 31. Asia-Pacific Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)
Figure 32. Asia-Pacific Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn
Figure 33. Asia-Pacific Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn
Figure 34. Asia-Pacific Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn
Figure 35. Asia-Pacific Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn
Figure 36. Asia-Pacific Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn
Figure 37. Asia-Pacific Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn
Figure 38. Asia-Pacific Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn
Figure 39. Asia-Pacific Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn
Figure 40. Breakdown of Asia-Pacific Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue
Figure 41. Asia-Pacific Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%)
Figure 42. Asia-Pacific Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn
Figure 43. Asia-Pacific Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn
Figure 44. Asia-Pacific Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn
Figure 45. Breakdown of APAC Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue
Figure 46. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 47. Pharmaceutical CDMO Market in Japan, 2019-2030, $ bn
Figure 48. Pharmaceutical CDMO Market in China, 2019-2030, $ bn
Figure 49. Pharmaceutical CDMO Market in Australia, 2019-2030, $ bn
Figure 50. Pharmaceutical CDMO Market in India, 2019-2030, $ bn
Figure 51. Pharmaceutical CDMO Market in South Korea, 2019-2030, $ bn
Figure 52. Pharmaceutical CDMO Market in Rest of APAC, 2019-2030, $ bn
Figure 53. Growth Stage of Asia-Pacific Pharmaceutical CDMO Industry over the Forecast Period
Note: Product cover images may vary from those shown
3 of 4
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
  • Charles River Laboratories
  • CMIC Co. Ltd
  • Covance Inc.
  • Hangzhou Tigermed Consulting Co Ltd
  • ICON Plc
  • IQVIA Holdings Inc.
  • LSK Global Pharma Service Co Ltd
  • Novotech Pty Ltd
  • PAREXEL International Corporation
  • Pharmaceutical Product Development LLC (PPD)
  • PRA Health Sciences Inc.
  • Quanticate Ltd
  • Samsung Bioepis Co. Ltd
  • SGS SA (SGS Life Sciences)
  • Syneos Health Inc.
  • WuXi AppTec Inc.
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll